AI Engines For more Details: Perplexity Kagi Labs You
Digestive Health: Bifidobacterium animalis has been shown to support digestive health by promoting the balance of gut microbiota. It helps in the breakdown of dietary fibers, production of short-chain fatty acids, and absorption of nutrients, thereby aiding in digestion and preventing gastrointestinal issues such as diarrhea, constipation, and irritable bowel syndrome (IBS).
Immune Function: This probiotic strain may enhance immune function by stimulating the production of immunoglobulins and promoting the activity of immune cells. By modulating the immune response, Bifidobacterium animalis helps the body defend against pathogens and reduces the risk of infections, particularly in the gut.
Allergic Conditions: Some studies suggest that Bifidobacterium animalis may have a beneficial effect on allergic conditions such as atopic dermatitis (eczema) and allergic rhinitis. It helps regulate the immune response, reduces inflammation, and strengthens the gut barrier, thereby potentially alleviating symptoms of allergic reactions.
Inflammatory Bowel Diseases (IBD): Bifidobacterium animalis has shown promise in the management of inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis. It helps maintain intestinal barrier function, modulate the inflammatory response, and restore microbial balance in the gut, leading to improvements in symptoms and disease activity.
Lactose Intolerance: Bifidobacterium animalis produces lactase enzyme, which helps break down lactose in the gut. Supplementation with Bifidobacterium animalis may improve lactose digestion and reduce symptoms of lactose intolerance, such as bloating, gas, and diarrhea.
Metabolic Health: There is evidence to suggest that Bifidobacterium animalis may have beneficial effects on metabolic health. It helps regulate blood sugar levels, improve insulin sensitivity, and reduce inflammation, thereby potentially lowering the risk of metabolic disorders such as type 2 diabetes and obesity.
Mood and Mental Health: Emerging research indicates a link between the gut microbiota and mental health. Bifidobacterium animalis may influence mood and cognitive function by producing neurotransmitters, modulating the gut-brain axis, and reducing systemic inflammation. It may help alleviate symptoms of depression, anxiety, and stress.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bifidobacterium adolescentis | Increases |
| species | Bifidobacterium bifidum | Increases |
| species | Bifidobacterium breve | Increases |
| species | Bifidobacterium catenulatum | Increases |
| species | Bifidobacterium longum | Increases |
| species | Bifidobacterium pseudocatenulatum | Increases |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.6 | 0.6 | |
| ADHD | 1.3 | -1.3 | |
| Allergic Rhinitis (Hay Fever) | 1.2 | 1.2 | |
| Allergies | 0.5 | 0.6 | -0.2 |
| Allergy to milk products | 0.9 | 0.9 | |
| Alzheimer's disease | 0.9 | 0.9 | 0 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.6 | -0.6 | |
| Ankylosing spondylitis | 0.6 | -0.6 | |
| Asthma | 0.3 | 0.6 | -1 |
| Atherosclerosis | 0.6 | -0.6 | |
| Atrial fibrillation | 0.6 | 0.6 | 0 |
| Autism | 1.3 | 0.6 | 1.17 |
| Brain Trauma | 0.9 | -0.9 | |
| Carcinoma | 0.6 | 0.6 | 0 |
| Celiac Disease | 1.2 | 0.2 | 5 |
| Cerebral Palsy | 0.6 | -0.6 | |
| Chronic Fatigue Syndrome | 0.6 | 0.6 | 0 |
| Colorectal Cancer | 0.6 | 0.6 | 0 |
| COVID-19 | 1.2 | 1 | 0.2 |
| Crohn's Disease | 0.9 | 0.6 | 0.5 |
| cystic fibrosis | 0.6 | 0.6 | |
| Depression | 1 | 1.7 | -0.7 |
| Dermatomyositis | 0.6 | 0.6 | |
| Eczema | 0.9 | 0.9 | |
| Endometriosis | 0.6 | -0.6 | |
| Epilepsy | 0.6 | 0.6 | 0 |
| Fibromyalgia | 0.6 | 0.6 | |
| Functional constipation / chronic idiopathic constipation | 0.6 | 0.8 | -0.33 |
| gallstone disease (gsd) | 0.6 | 0.6 | |
| Generalized anxiety disorder | 0.8 | 0.8 | |
| Graves' disease | 0.6 | -0.6 | |
| Hashimoto's thyroiditis | 0.6 | 0.6 | 0 |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.3 | 0.6 | -1 |
| hyperglycemia | 0.6 | 0.6 | |
| Hyperlipidemia (High Blood Fats) | 0.6 | -0.6 | |
| hypertension (High Blood Pressure | 0.6 | 0.6 | 0 |
| Hypothyroidism | 0.6 | 0.6 | |
| IgA nephropathy (IgAN) | 0.6 | 0.6 | |
| Inflammatory Bowel Disease | 0.8 | 0.6 | 0.33 |
| Irritable Bowel Syndrome | 0.6 | 0.6 | 0 |
| Liver Cirrhosis | 0.6 | 0.6 | 0 |
| Long COVID | 1.2 | 1.1 | 0.09 |
| ME/CFS with IBS | 0.6 | 0.6 | |
| ME/CFS without IBS | 0.6 | 0.6 | |
| Menopause | 0.2 | 0.4 | -1 |
| Metabolic Syndrome | 1.6 | 1.1 | 0.45 |
| Mood Disorders | 1.3 | 1.7 | -0.31 |
| Multiple Sclerosis | 0.8 | -0.8 | |
| Multiple system atrophy (MSA) | 0.8 | 0.8 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.2 | 1.2 | |
| NonCeliac Gluten Sensitivity | 0.6 | 0.6 | |
| Obesity | 0.8 | 0.6 | 0.33 |
| obsessive-compulsive disorder | 0.8 | 0.8 | |
| Osteoarthritis | 0.2 | 0.2 | |
| Parkinson's Disease | 0.2 | 1.1 | -4.5 |
| Polycystic ovary syndrome | 0.6 | 0.6 | |
| Postural orthostatic tachycardia syndrome | 0.6 | 0.6 | |
| Premenstrual dysphoric disorder | 0.6 | -0.6 | |
| Psoriasis | 0.6 | -0.6 | |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.6 | 0.9 | -0.5 |
| Rosacea | 0.6 | -0.6 | |
| Schizophrenia | 0.9 | 1 | -0.11 |
| Sjögren syndrome | 0.8 | 0.8 | |
| Sleep Apnea | 0.6 | -0.6 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.2 | 0.2 | |
| Stress / posttraumatic stress disorder | 0.6 | 0.6 | 0 |
| Systemic Lupus Erythematosus | 0.6 | 0.6 | |
| Tic Disorder | 0.6 | 0.6 | |
| Type 1 Diabetes | 0.4 | 0.4 | |
| Type 2 Diabetes | 1 | 1.1 | -0.1 |
| Ulcerative colitis | 0.8 | 0.9 | -0.13 |
| Unhealthy Ageing | 0.6 | 0.6 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.